Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;56(1):2305309.
doi: 10.1080/07853890.2024.2305309. Epub 2024 Jan 23.

Prognostic value of plasma secretoneurin concentration in patients with heart failure with reduced ejection fraction in one-year follow-up

Łukasz Wołowiec  1 , Daniel Rogowicz  1 , Jacek Budzyński  2 , Joanna Banach  1 , Anna Wołowiec  3 , Mariusz Kozakiewicz  3 , Maciej Bieliński  4 , Albert Jaśniak  1 , Joanna Osiak  1 , Grzegorz Grześk  1
Affiliations

Prognostic value of plasma secretoneurin concentration in patients with heart failure with reduced ejection fraction in one-year follow-up

Łukasz Wołowiec et al. Ann Med. 2024 Dec.

Abstract

Background: This is the first study to examine the clinical utility of measuring plasma secretoneurin (SN) levels in patients with heart failure with reduced ejection fraction (HFrEF), as a predictor of unplanned hospitalization, and all-cause mortality independently, and as a composite endpoint at one-year follow-up.

Methods: The study group includes 124 caucasian patients in New York Heart Association (NYHA) classes II to IV. Plasma SN concentrations were statistically analyzed in relation to sex, age, BMI, etiology of HFrEF, pharmacotherapy, clinical, laboratory and echocardiographic parameters. Samples were collected within 24 h of admission to the hospital.

Key results: In the 12-month follow-up, high SN levels were noted for all three endpoints.

Conclusions: SN positively correlates with HF severity measured by NYHA classes and proves to be a useful prognostic parameter in predicting unplanned hospitalizations and all-cause mortality among patients with HFrEF. Patients with high SN levels may benefit from systematic follow-up and may be candidates for more aggressive treatment.

Keywords: HFrEF; Secretoneurin; biomarker; cardiovascular system; heart failure.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
STARD diagram to report flow of participants through the study.
Figure 2.
Figure 2.
Kaplan Meier’s plot for HFrEF patients survival in relation to plasma SN concentration.
Figure 3.
Figure 3.
Kaplan Meier’s plot for HFrEF patients survival in relation to plasma NT-proBNP concentration.
Figure 4.
Figure 4.
Kaplan Meier’s plot for HFrEF patients survival in relation to age.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Long-acting relaxin analogues: a novel tool in cardiology.
    Wołowiec Ł, Jaśniak A, Osiak-Gwiazdowska J, Czaplińska D, Szymczak A, Pęcherz JA, Grześk G. Wołowiec Ł, et al. Front Pharmacol. 2025 Aug 4;16:1626469. doi: 10.3389/fphar.2025.1626469. eCollection 2025. Front Pharmacol. 2025. PMID: 40832606 Free PMC article. Review.

References

    1. Plášek J, Lazárová M, Dodulík J, et al. . Secretoneurin as a novel biomarker of cardiovascular episodes: are we there yet? A narrative review. J Clin Med. 2022;11(23):1. doi:10.3390/jcm11237191. - DOI - PMC - PubMed
    1. Brynildsen J, Myhre PL, Lyngbakken MN, et al. . Circulating secretoneurin concentrations in patients with moderate to severe aortic stenosis. Clin Biochem. 2019a;71:17–11. doi:10.1016/j.clinbiochem.2019.06.008. - DOI - PubMed
    1. Brynildsen J, Petäjä L, Myhre PL, et al. . Circulating secretoneurin concentrations after cardiac surgery: data from the FINNish acute kidney injury heart study. Crit Care Med. 2019b;47(5):e412–e419. doi:10.1097/CCM.0000000000003670. - DOI - PubMed
    1. Myhre PL, Ottesen AH, Faaren AL, et al. . Performance of a novel research-use-Only secretoneurin ELISA in ­patients with suspected acute coronary syndrome: comparison with an established secretoneurin radioimmunoassay. Cardiology. 2021;146(5):566–574. doi:10.1159/000517444. - DOI - PubMed
    1. Ottesen AH, Carlson CR, Eken OS, et al. . Secretoneurin is an endogenous calcium/Calmodulin-Dependent protein kinase II inhibitor that attenuates Ca2+-dependent arrhythmia. Circ Arrhythm Electrophysiol. 2019;12(4):e007045. doi:10.1161/CIRCEP.118.007045. - DOI - PubMed